Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Networking & Security
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
University of North Dakota manages a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently contains 3 pending office actions. These actions are distributed across 2 distinct art units, indicating that the university's active patent applications cover multiple technical sub-sectors within the biotechnology field. This level of activity suggests a diverse research and development focus.
The prosecution involves 3 distinct examiners, providing a variety of perspectives on the pending claims. AGUIRRE, AMANDA L is identified as the busiest examiner, though this examiner is only responsible for 1 pending office action. Since there are 3 pending office actions in total, the workload is evenly distributed among the 3 distinct examiners. This diversification across examiners and art units suggests a broad patent strategy that requires managing different examiner expectations. For a practitioner, this means that the prosecution strategy must be adapted to the specific preferences of 3 distinct examiners across 2 distinct art units.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (67%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| AGUIRRE, AMANDA L | 1 | 77.2% | +15.6% |
| COUGHLIN, MATTHEW P | 1 | 71.3% | +12.4% |
| ABDULLAH, SAAD AHMAD | 1 | 74.1% | +30.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18250493 | USE OF SMALL MOLECULE FAK ACTIVATORS TO PROMOTE MUCOSAL HEALING | AGUIRRE, AMANDA L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17183926 | AUTONOMOUS VEHICLE CONTROL ATTACK DETECTION AND COUNTERMEASURES | ABDULLAH, SAAD AHMAD | 53d overdue |
| 17190177 | PROANGIOGENIC COMPOSITIONS AND METHODS OF USE | COUGHLIN, MATTHEW P | 28d |
| 18250493 | USE OF SMALL MOLECULE FAK ACTIVATORS TO PROMOTE MUCOSAL HEALING | AGUIRRE, AMANDA L | — |
| Art Unit | Apps |
|---|---|
| 1626 | 2 |
| 2431 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18250493 | USE OF SMALL MOLECULE FAK ACTIVATORS TO PROMOTE MUCOSAL HEALING | AGUIRRE, AMANDA L | 1626 | §102§103§112Other | Non-Final OA | — | Pending | Apr 25, 2023 |
| 17190177 | PROANGIOGENIC COMPOSITIONS AND METHODS OF USE | COUGHLIN, MATTHEW P | 1626 | §103 | Final Rejection | 28d | Pending | Mar 02, 2021 |
| 17183926 | AUTONOMOUS VEHICLE CONTROL ATTACK DETECTION AND COUNTERMEASURES | ABDULLAH, SAAD AHMAD | 2431 | §103 | Non-Final OA | 53d overdue | Pending | Feb 24, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial